BIRC7: A Potential Drug Target for Melanoma and Other Cancers

Target Name: BIRC7

NCBI ID: G79444

BIRC7

BIRC7: A Potential Drug Target for Melanoma and Other Cancers

BIRC7 (Melanoma Invasive Transforming Signaling Protein 7) is a protein that is expressed in melanoma, which is a type of skin cancer. It is known for its role in the development and progression of melanoma, and for its potential as a drug target.

BIRC7 is a transmembrane protein that is expressed in various tissues, including the skin, cancer cells, and immune cells. It is made up of four structural domains: an extracellular domain, a transmembrane domain, an intracellular domain, and a C-terminal domain.

The extracellular domain of BIRC7 is composed of a long amino acid sequence that is involved in the formation of a complex with other proteins, including the transcription factor NF-kappa-B. This interaction between BIRC7 and NF-kappa-B is important for the regulation of various cellular processes, including cell growth, differentiation, and inflammation.

The transmembrane domain of BIRC7 is made up of a protein that is involved in the formation of a transmembrane signal transduction cascade. This cascade is involved in the regulation of various cellular processes, including the regulation of cell adhesion, migration, and invasion.

The intracellular domain of BIRC7 is composed of a protein that is involved in the regulation of various cellular processes, including cell growth, differentiation, and apoptosis. This domain is also involved in the interaction between BIRC7 and the transcription factor NF-kappa-B.

The C-terminal domain of BIRC7 is composed of a protein that is involved in the regulation of various cellular processes, including cell growth, differentiation, and apoptosis. This domain is also involved in the interaction between BIRC7 and the transcription factor NF-kappa-B.

BIRC7 is a protein that is expressed in various tissues, including the skin, cancer cells, and immune cells. It is involved in the regulation of various cellular processes, including cell growth, differentiation, and apoptosis. The interaction between BIRC7 and the transcription factor NF-kappa-B is important for the regulation of these processes. As a result, BIRC7 is a potential drug target for the treatment of melanoma and other cancers.

In conclusion, BIRC7 is a protein that is involved in the regulation of various cellular processes, including cell growth, differentiation, and apoptosis. It is expressed in various tissues, including the skin, cancer cells, and immune cells. The interaction between BIRC7 and the transcription factor NF-kappa-B is important for the regulation of these processes. As a result, BIRC7 is a potential drug target for the treatment of melanoma and other cancers. Further research is needed to fully understand the role of BIRC7 in the development and progression of cancer, as well as its potential as a drug target.

Protein Name: Baculoviral IAP Repeat Containing 7

Functions: Apoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control (PubMed:11162435, PubMed:11024045, PubMed:11084335, PubMed:16729033, PubMed:17294084). Its anti-apoptotic activity is mediated through the inhibition of CASP3, CASP7 and CASP9, as well as by its E3 ubiquitin-protein ligase activity (PubMed:11024045, PubMed:16729033). As it is a weak caspase inhibitor, its anti-apoptotic activity is thought to be due to its ability to ubiquitinate DIABLO/SMAC targeting it for degradation thereby promoting cell survival (PubMed:16729033). May contribute to caspase inhibition, by blocking the ability of DIABLO/SMAC to disrupt XIAP/BIRC4-caspase interactions (PubMed:16729033). Protects against apoptosis induced by TNF or by chemical agents such as adriamycin, etoposide or staurosporine (PubMed:11162435, PubMed:11084335, PubMed:11865055). Suppression of apoptosis is mediated by activation of MAPK8/JNK1, and possibly also of MAPK9/JNK2 (PubMed:11865055). This activation depends on TAB1 and MAP3K7/TAK1 (PubMed:11865055). In vitro, inhibits CASP3 and proteolytic activation of pro-CASP9 (PubMed:11024045)

The "BIRC7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BIRC7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets